findmyKOL
Clinical trialNCT05709574Active, not recruitingPhase 2Interventional

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

SponsorUniversity of ArizonaEnrollment11Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Arizona Cancer Center at Umc North/university Medical Center

    Tucson, Arizona, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Apr 2023
Primary completion
3 Jun 2026
Completion
30 Oct 2026
Last update posted
2 Jul 2026
Registered enrollment
11
Registry id
NCT05709574

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.